A drug discovery & development solutions company with a global presence.
Joined December 2016
- Tweets 3,135
- Following 134
- Followers 4,039
- Likes 759
2,638 Photos and videos
Drug toxicity is a leading cause of failure in development. Early toxicity identification can change that. At Cyprotex, we use advanced in vitro models to identify safety risks early— ensuring the safest compounds reach the clinic. Learn more about our services here: hubs.ly/Q03bgjld0
Get in touch to discuss your project at enquiries@cyprotex.com
#theadmetoxspecialists #cyprotex #toxicology
2
3
1,489
A deep understanding of ADME is essential for successful drug discovery and development. Now updated with the latest ICH M12 guidelines, the 6th edition of Cyprotex’s ADME Guide is here for you to explore more.
Join thousands of scientists who rely on this must-have resource for optimizing compound design and development.
Download your free copy today! hubs.ly/Q038XPjm0
#cyprotex #theadmetoxspecialists
1
3
815
Drug-drug interactions (DDIs) are a major concern in drug development, and staying compliant with evolving regulatory guidelines is more critical than ever. 4th edition of Cyprotex’s DDI Guide breaks down the impact of the latest ICH M12 guidelines on your DDI studies — helping you navigate with clarity and confidence.
#cyprotex #theadmetoxspecialists
1
1
640
Download your free copy today! evotec.com/sciencepool/drug-…
1
464
Meet the Evotec team at #SLAS2025 hubs.ly/Q032Zcxm0
Dirk Winkler, SVP #HitIdentification, will be presenting on #AI #ML integration and its value in accelerating #DrugDiscovery.
Schedule a meeting with Dirk at booth #850 by contacting info@evotec.com.
2
564
Meet our team at booth #805 and learn about our research at #SLAS2025. hubs.ly/Q032dfq60.
Mélanie Carquin PhD, Team Leader in Evotec’s HTP Biology & Screening group, will be presenting research on RNA #SplicingModulators and their role in drugging ‘undruggable’ targets.
1
4
633
Just - Evotec Biologics is using #AI and #ML to revolutionize #biopharma discovery with a Humanoid #Antibody Library. Our latest publication shows how we validated it by isolating antibodies against SARS-CoV-2. Learn more here-
hubs.ly/Q02SjTJX0
3
496
Improve your success in hit identification!
Watch on-demand our Quality Hits at Lightning Speed webinar series hubs.ly/Q02_V5Kr0.
Contact us to find out how Evotec can accelerate your project: info@evotec.com
#HitIdentification #HighThroughputScreening #DrugDiscovery
4
478
Read our blog article and learn more about Evotec's end-to-end capabilities for the synthesis, purification, isolation, and quality control of complex modified Oligonucleotides, such as ASOs and siRNAs.
hubs.ly/Q02-B3SW0
#Oligonucleotides #OligonucleotideDrugDiscovery
5
377
Missed our joint webinar with Promega, Enabling High-Throughput Screening and Characterization of Targeted Protein Degraders with HiBiT Technology? Watch it now on-demand!
hubs.ly/Q02_k8w40?
#HighThroughputScreening #TargetedProteinDegraders
2
424
In 2022, Evotec committed to the SBTi Net Zero strategy and we’re making significant progress. With Armstrong International’s innovative heat pump tech, we’ve optimized energy use and cut emissions at our Verona site.
Learn more in our latest blog post! hubs.ly/Q02-B5kX0
1
383
Evotec SE announced that its #DrugDiscovery accelerator with Novo Nordisk, LAB eN², has selected its first three projects to move forward in the program.
To learn more, read the full press release here-
hubs.ly/Q02_7mp60
#TogetherForMedicinesThaMatter
2
7
956
How to turn a poorly soluble drug into a high performing formulation in just six weeks with scarce API availability? Now on-demand - our case study webinar on ID11916 presented by our #EarlyFormulation expert Fabrizio Fina.
hubs.ly/Q02ZZ8nw0
#API #Solubility
1
257
Now available on-demand - Episode 3 of Evotec's Oligonucleotide Webinar Series exploring innovative tissue engineering and regenerative medicine approaches using miRNAs to treat skeletal injuries.
hubs.ly/Q02YcdQZ0
#Oligonucleotides #RegenerativeMedicine #miRNA
3
325
Last chance to register and be part of this groundbreaking webinar!
High-Sensitivity Proteomics: The Next Frontier for Spatial and Single-Cell #Biology.
Register now and advance your research with high-sensitivity proteomics: hubs.ly/Q02-6SV20
#Biologics #Proteomics
3
268
Join us on December 10 for the 4th episode of our webinar series on oligo therapies! Dr. Marie Wikström Lindholm, CSO at Silence Therapeutics, will present on: Therapeutic siRNAs: Considerations for “Picking the Best One”.
To register: hubs.ly/Q02-7qJ20
#Oligonucleotides
2
249
Read our new article, published in Nature's Biopharma Dealmakers, to learn how we combine therapeutic area expertise with an arsenal of technologies to develop innovative #CellTherapies for a range of disease areas.
hubs.ly/Q02-6f1P0
#iPSC #Immunology #Inflammation
2
216
Our T-Cell Immunogenicity Risk Panel delivers critical data on the human immune response triggered by your biotherapeutic. By measuring IL-2 and IFN-γ release from PBMCs, we enable you to identify T-cell mediated immunogenic risks with better precision.
#cyprotex #immunotox
1
2
393